Definium Therapeutics Inc (DFTX) Announces Sufficient Cash to Fund Operations through 2028

Definium Therapeutics Inc (NASDAQ:DFTX) has reported cash sufficient to fund operations into 2028, with $411.6 million in cash and cash equivalents and investments. The company is focused on developing drugs to treat mental health disorders, with its lead drug candidate DT120 in Phase 3 trials for major depressive disorder and generalized anxiety disorder. Topline data from the Emerge Phase 3 MDD trial is expected in late Q2 2026, and initial study data from the Phase 2a trial for DT402 is expected in 2026.